Principal Financial Group Inc. Reduces Stake in Immunocore Holdings PLC Sponsored ADR $IMCR

Principal Financial Group Inc. lessened its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 21.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 519,130 shares of the company’s stock after selling 139,306 shares during the period. Principal Financial Group Inc.’s holdings in Immunocore were worth $15,652,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Leonteq Securities AG acquired a new stake in Immunocore during the 4th quarter valued at approximately $30,000. Harbour Investments Inc. increased its stake in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares during the period. Rockefeller Capital Management L.P. purchased a new position in shares of Immunocore during the fourth quarter worth $47,000. Arax Advisory Partners raised its holdings in shares of Immunocore by 302.9% during the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after purchasing an additional 1,042 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Immunocore by 37.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after purchasing an additional 572 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Price Performance

NASDAQ:IMCR opened at $35.51 on Friday. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $27.56 and a 52 week high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The stock has a market capitalization of $1.81 billion, a PE ratio of -64.56 and a beta of 0.73. The stock’s 50-day moving average price is $30.59 and its 200-day moving average price is $31.28.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The company had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, equities analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IMCR shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a report on Monday. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Immunocore has a consensus rating of “Hold” and an average price target of $56.71.

Immunocore Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.